Subthreshold α2-Adrenergic Activation Counteracts Glucagon-Like Peptide-1 Potentiation of Glucose-Stimulated Insulin Secretion. (15th December 2010)

• Record Type: Journal Article
• Authors: Pan, Minglin; Yang, Guang; Cui, Xiuli; Yang, Shao-Nian
• Other Names: Rotella Carlo M. Academic Editor.
• Is Part Of: Experimental diabetes research. Volume 2011(2011)
• Publication Date: 2010-12-15
• Subjects: Diabetes -- Research -- Periodicals; Diabetes -- Research; Periodicals; 616.462
• DOI: 10.1155/2011/604989
• Languages: English
• ISSNs: 1687-5214

Abstract

Abstract : The pancreatic β cell harbors α 2 -adrenergic and glucagon-like peptide-1 (GLP-1) receptors on its plasma membrane to sense the corresponding ligands adrenaline/noradrenaline and GLP-1 to govern glucose-stimulated insulin secretion. However, it is not known whether these two signaling systems interact to gain the adequate and timely control of insulin release in response to glucose. The present work shows that the α 2 -adrenergic agonist clonidine concentration-dependently depresses glucose-stimulated insulin secretion from INS-1 cells. On the contrary, GLP-1 concentration-dependently potentiates insulin secretory response to glucose. Importantly, the present work reveals that subthreshold α 2 -adrenergic activation with clonidine counteracts GLP-1 potentiation of glucose-induced insulin secretion. This counteractory process relies on pertussis toxin- (PTX-) sensitive Gi proteins since it no longer occurs following PTX-mediated inactivation of Gi proteins. The counteraction of GLP-1 potentiation of glucose-stimulated insulin secretion by subthreshold α 2 -adrenergic activation is likely to serve as a molecular mechanism for the delicate regulation of insulin release.